Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.43 |
| ▸ | GHSR | Q92847 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | MMP8 | P22894 | 4/20 | 0.39 |
| ▸ | MMP3 | P08254 | 2/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5454912 | 0.84 | HRH3 (0.47) | MAPTKMT2AL3MBTL1ALDH1A1POLB | |
| SCHEMBL5466214 | 0.83 | KMT2A (0.42) | MAPTKMT2AHRH3GHSRDRD3 | |
| SCHEMBL5451236 | 0.81 | L3MBTL1 (0.50) | KMT2AL3MBTL1ALDH1A1HRH3DRD3 | |
| SCHEMBL5454888 | 0.77 | MEN1 (0.55) | MAPTKMT2AALDH1A1HRH3DRD3 | |
| SCHEMBL5463839 | 0.74 | HRH3 (0.60) | HRH3DRD3DRD2HTR6HRH1 | |
| SCHEMBL5458846 | 0.74 | HRH3 (0.74) | KMT2AL3MBTL1ALDH1A1HRH3DRD3 | |
| SCHEMBL5462293 | 0.73 | HRH3 (0.46) | HRH3DRD3DRD2HTR6HRH1 | |
| SCHEMBL5466240 | 0.73 | MEN1 (0.57) | KMT2AALDH1A1POLBHRH3MEN1 | |
| SCHEMBL5464188 | 0.73 | HRH3 (0.55) | KMT2AALDH1A1HRH3DRD3DRD2 | |
| SCHEMBL5466147 | 0.73 | HRH3 (0.46) | KMT2AALDH1A1HRH3DRD3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | CNR2, GRIN2C, GRIN2B | MAPT 1504/4885KMT2A 390/4885L3MBTL1 3089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.